MHAT ''Sveta Petka" AD
About MHAT ''Sveta Petka" AD
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at MHAT ''Sveta Petka" AD
During the past decade, MHAT ''Sveta Petka" AD conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on
average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
2011-12-01
2018-12-14
Completed
51
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
2016-09-01
2023-08-01
Active, not recruiting
539
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
2020-10-12
2025-06-30
Recruiting
31
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
2021-05-26
2025-06-01
Active, not recruiting
212
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
2021-05-27
2026-05-23
Recruiting
440
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
2021-02-25
2025-08-23
Recruiting
309
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
2022-06-23
2033-01-26
Recruiting
864
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "MHAT ''Sveta Petka" AD"
#1 collaborator was "Gilead Sciences" with 3 trials as a collaborator and "Galapagos NV" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at MHAT ''Sveta Petka" AD
According to Clinical.Site data, the most researched conditions in "MHAT ''Sveta Petka" AD" are
"Crohn's Disease" (2 trials), "Ulcerative Colitis" (2 trials) and "Clostridium Difficile Infection" (1 trials). Many other conditions were trialed in "MHAT ''Sveta Petka" AD" in a lesser frequency.
Clinical Trials Intervention Types at MHAT ''Sveta Petka" AD
Most popular intervention types in "MHAT ''Sveta Petka" AD" are "Drug" (4 trials) and "Biological" (1 trials). Other intervention types were less common.
The name of intervention was led by "Filgotinib" (4 trials), "Placebo" (3 trials), "Clostridium difficile vaccine" (1 trials), "PTM filgotinib" (1 trials) and "Placebo to match filgotinib" (1 trials). Other intervention names were less common.
Clinical Trials Genders at MHAT ''Sveta Petka" AD
The vast majority of trials in "MHAT ''Sveta Petka" AD" are
5 trials for "All" genders.
Clinical Trials Status at MHAT ''Sveta Petka" AD
Currently, there are NaN active trials in "MHAT ''Sveta Petka" AD".
undefined are not yet recruiting,
undefined are recruiting,
1 are Active, not recruiting,
and 1 are Enrolling by invitation.
In total, there were 3 completed trials in MHAT ''Sveta Petka" AD,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in MHAT ''Sveta Petka" AD, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 5 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".